Envista Holdings Corporation acquired Osteogenics Biomedical, Inc. (with Allotech LLC and OBI Biologics, Inc.) for approximately $128.2 million, a transaction completed in July 2022, structured as all cash.
Osteogenics Biomedical, Inc. (with Allotech LLC and OBI Biologics, Inc.) operates in Specialty Products & Technologies, is based in United States (products sold worldwide). Envista acquired all of the equity of Osteogenics Biomedical, Inc., Allotech LLC and OBI Biologics, Inc. (together 'Osteogenics') for total consideration of approximately $128.2 million, under an Equity Purchase Agreement dated May 17, 2022, closing on July 5, 2022. Osteogenics develops regenerative solutions for periodontists, oral and maxillofacial surgeons, and clinicians involved in implant dentistry worldwide, and became part of the Specialty Products & Technologies segment. (date_announced reflects the disclosed agreement signing date; there was no dedicated 8-K.)
Expand Envista's specialty and implant-adjacent portfolio with regenerative solutions used in periodontics, oral/maxillofacial surgery and implant dentistry.
Strengthens the implant/specialty franchise with regenerative and bone-graft products for surgical dental procedures. Complements Nobel Biocare implant and specialty offerings within Specialty Products & Technologies. Specialty Products & Technologies segment
On July 5, 2022, the Company acquired all of the equity of Osteogenics Biomedical Inc., Allotech LLC and OBI Biologics, Inc. (together "Osteogenics") for total consideration of approximately $128.2 million ... Osteogenics develops innovative regenerative solutions for periodontists, oral and maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world, and is part of the Company's Specialty Products & Technologies segment.Envista Holdings Corporation FY2022 Form 10-K, Note 3 Acquisitions
Advisory firms were not disclosed for this transaction.